Trials / Completed
CompletedNCT01180049
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | temsirolimus | 175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit |
| DRUG | temsirolimus | 75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2015-11-01
- Completion
- 2018-06-01
- First posted
- 2010-08-11
- Last updated
- 2019-05-20
- Results posted
- 2017-05-19
Locations
31 sites across 11 countries: United States, Australia, Czechia, France, Germany, Italy, Poland, Romania, Russia, Serbia, South Korea
Source: ClinicalTrials.gov record NCT01180049. Inclusion in this directory is not an endorsement.